Liposarcoma
📧 Sign up to get email alerts when something new happens for Liposarcoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-21Clinical Trial Update: NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) [Phase 1, Phase 2]
This is a clinical trial protocol update for NRSTS2021, a Phase 1/2 study evaluating maintenance pazopanib, limited-margin radiation therapy…
-
CLINICAL_TRIALS research · 2026-04-21Clinical Trial Update: Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma [Phase 2]
A Phase 2 clinical trial update describes testing the combination of ipilimumab and nivolumab with or without cabozantinib in adults with ad…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery [Phase 2]
Clinical trial update for a Phase 2 study evaluating Talimogene laherparepvec with radiation therapy in newly diagnosed soft tissue sarcoma …
-
CLINICAL_TRIALS research · 2026-04-09Clinical Trial Update: Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors [Phase 1, Phase 2]
Clinical trial evaluating silmitasertib (CX-4945) in combination with chemotherapy for relapsed or refractory solid tumors; Phase 1 and Phas…
-
CLINICAL_TRIALS trial_result · 2026-04-08Clinical Trial Update: Eribulin and Radiation Therapy in Treating Patients With Retroperitoneal Liposarcoma That Can Be Removed by Surgery [Phase 1]
Phase 1 clinical trial update assessing eribulin in combination with radiation therapy for patients with surgically resectable retroperitone…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-06Clinical Trial Update: Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors [Phase 1]
Phase 1 trial evaluating an IL-15/IL-21 armored GPC3-targeted CAR-T cell therapy for pediatric solid tumors is currently recruiting.
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma [Phase 3]
A Phase 3 clinical trial is evaluating whether adding neoadjuvant chemotherapy to surgery improves outcomes for high-risk retroperitoneal sa…
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: Evaluation of Abemaciclib and Radiation Therapy Before Surgery for the Treatment of High-Risk Adipocytic Retroperitoneal Sarcoma [Phase 1]
Phase 1 trial evaluating the combination of abemaciclib with radiation therapy before surgical resection in patients with high-risk adipocyt…
-
CLINICAL_TRIALS trial_result · 2026-03-06Clinical Trial Update: Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors [Phase 1]
Phase 1 trial evaluating IL-15 armored glypican-3–specific CAR-T cells for solid tumors, including hepatocellular carcinoma and several pedi…
-
CLINICAL_TRIALS research · 2026-02-25Clinical Trial Update: Precision Medicine Approaches for Neoadjuvant Therapy in High-risk Sarcoma Patients
Clinical trial update describing precision medicine approaches for neoadjuvant therapy in high‑risk sarcoma patients; currently recruiting.
-
EMA approval · 2026-02-24EMA Authorised: Eribulin Baxter (Eribulin mesylate) — Baxter Holding B.V.
EMA authorised Eribulin Baxter (eribulin mesylate) for treatment of breast neoplasms and liposarcoma; the marketing authorisation holder is …
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells [Phase 1]
Phase 1 pediatric trial of interleukin-15 and interleukin-21 armored glypican-3–specific CAR T cells for solid tumors, including liver-origi…
-
CLINICAL_TRIALS research · 2026-01-28Clinical Trial Update: Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma. [Phase 2]
Clinical trial evaluating dose-escalated, hypofractionated definitive proton radiotherapy for patients with inoperable soft tissue sarcoma (…
-
CLINICAL_TRIALS research · 2026-01-28Clinical Trial Update: Hypofractionated, 3-week, Preoperative Proton or X-ray Radiotherapy for Patients With Localized Soft Tissue Sarcoma [Phase 2]
Phase 2 clinical trial update evaluating hypofractionated, 3-week preoperative radiotherapy using proton or photon therapy for localized sof…
-
CLINICAL_TRIALS trial_result · 2026-01-21Clinical Trial Update: Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors [Phase 1]
This is an update on a Phase 1 trial of interleukin-15 armored GPC3-specific CAR-T cells for pediatric solid tumors, with results posted and…
-
CLINICAL_TRIALS trial_result · 2026-01-09Clinical Trial Update: Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma [Phase 3]
Phase 3 Brightline-4 trial evaluating brigimadlin tolerability in patients with dedifferentiated liposarcoma has completed.
-
CLINICAL_TRIALS trial_result · 2025-11-04Clinical Trial Update: Cytokine Armored GPC3 Specific Chimeric Antigen Receptor Expressing T-cells in Adults With Solid Tumors [Phase 1]
Phase 1 trial evaluating cytokine-armored GPC3-targeted CAR-T cells in adults with solid tumors, including hepatocellular carcinoma; the stu…
-
CLINICAL_TRIALS research · 2025-11-03Clinical Trial Update: Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells [Phase 1]
Phase 1 clinical trial evaluating GPC3-targeted CAR T cells armored with IL-15 and IL-21 for GPC3-positive solid tumors; currently recruitin…
-
CLINICAL_TRIALS research · 2025-10-31Clinical Trial Update: BTX-A51 in Patients With Liposarcoma or CIC-rearranged Sarcoma [Phase 1]
This ClinicalTrials.gov update reports that a Phase 1 study of BTX-A51 is currently recruiting for liposarcoma and CIC-rearranged sarcoma, i…
-
CLINICAL_TRIALS research · 2025-10-24Clinical Trial Update: Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma [Phase 1]
Phase 1 clinical trial evaluating the combination of zanzalintinib and eribulin in patients with advanced liposarcoma and leiomyosarcoma; re…
-
CLINICAL_TRIALS research · 2025-10-01Clinical Trial Update: Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors [Phase 2]
Phase 2 study to assess safety and tolerability of PF-07220060 in adults with advanced solid tumors; the trial is currently ACTIVE_NOT_RECRU…
-
CLINICAL_TRIALS trial_result · 2025-08-28Clinical Trial Update: A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas [Phase 2]
A Phase II study evaluating the combination of eribulin and pembrolizumab in soft tissue sarcomas has completed, with results posted.
-
FDA approval · 2025-08-05FDA Approved: ERIBULIN MESYLATE — Original Application (Kindos Pharmaceuticals Co., Ltd.)
FDA approves an original application for Eribulin Mesylate from Kindos Pharmaceuticals Co., Ltd., enabling its generic product to enter the …
-
CLINICAL_TRIALS research · 2025-07-24Clinical Trial Update: MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma [Phase 2]
A Phase 2 trial evaluating MASCT-I in combination with doxorubicin and ifosfamide as first-line therapy for advanced soft tissue sarcoma is …
-
FDA approval · 2025-07-03FDA Approved: ERIBULIN MESYLATE — Original Application (Dr. Reddys Laboratories Inc)
FDA approves Dr. Reddy's Laboratories' original ANDA for eribulin mesylate, a generic version of the anticancer agent.